Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

225
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
225
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

186
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
186
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

412
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
412
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

297
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
297
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

304
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth Differentiation Factor-15 Could Predict Decreased Hemoglobin in Tuberculosis Treated With Linezolid-Containing Regimen.

The clinical respiratory journal·2026
Same author

Diagnostic Performance of New Commercial IGRAs for Mycobacterium tuberculosis Infection: An updated Systematic Review and Meta-analysis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysis.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Strength of ATLAS or lady luck in a sepsis management trial?

The Lancet. Infectious diseases·2026
Same author

Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial.

The Journal of infectious diseases·2026
Same author

Functional Outcomes, Lung health and Livelihood Outcomes among people With Tuberculosis (FOLLOW-TB): study protocol for a multicentre, prospective cohort study in Canada.

BMJ open·2025
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Aug 24, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Testing and Treating Mycobacterium tuberculosis Infection.

Edgar Ortiz-Brizuela1, Dick Menzies2, Marcel A Behr2

  • 1Department of Epidemiology, Biostatistics & Occupational Health, McGill University, 1020 Pine Avenue, West Montreal, H3A 1A2, Canada; McGill International TB Centre, Research Institute of the McGill University Health Centre, 5252 boul.de Maisonneuve, West Montreal, Quebec, H4A 3S5, Canada; Department of Medicine, Insituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, Mexico City, 14000, Mexico.

The Medical Clinics of North America
|October 24, 2022
PubMed
Summary
This summary is machine-generated.

Preventing tuberculosis (TB) requires identifying high-risk individuals post-Mycobacterium tuberculosis infection for timely treatment. Rifamycin-based regimens offer the best balance of efficacy and safety for TB preventive therapy.

Keywords:
DiagnosisMycobacterium tuberculosisTreatmentTuberculosis

More Related Videos

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format
12:39

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Published on: June 24, 2011

38.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Related Experiment Videos

Last Updated: Aug 24, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format
12:39

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Published on: June 24, 2011

38.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Area of Science:

  • Infectious Diseases
  • Public Health
  • Microbiology

Background:

  • Mycobacterium tuberculosis infection does not always lead to active tuberculosis disease (TB).
  • Progression to TB is more likely in individuals with known risk factors, especially within the first year post-infection.
  • Targeted testing and treatment of high-risk individuals optimize the benefits of TB preventive therapy.

Purpose of the Study:

  • To review the diagnosis and treatment of Mycobacterium tuberculosis infection.
  • To summarize clinical scenarios for managing TB infection.
  • To highlight the importance of risk stratification in TB prevention.

Main Methods:

  • Literature review of diagnostic and therapeutic strategies for TB infection.
  • Analysis of risk factors influencing progression from infection to disease.
  • Evaluation of available treatment options for TB preventive therapy.

Main Results:

  • Rifamycin-based regimens demonstrate the optimal efficacy-safety profile for TB treatment.
  • Risk-based screening maximizes the benefits of TB preventive therapy while minimizing potential harms.
  • Early identification and intervention are crucial for preventing TB disease progression.

Conclusions:

  • Effective management of Mycobacterium tuberculosis infection relies on accurate diagnosis and risk assessment.
  • Strategic application of TB preventive therapy, particularly rifamycin-based regimens, is key to controlling TB.
  • Clinical guidelines should prioritize testing and treatment for high-risk populations.